S&C Client Teva Pharmaceuticals Completes $40.5 Billion Acquisition of Allergan’s Generics Business

August 2, 2016

S&C client Teva Pharmaceutical Industries completed its $40.5 billion acquisition of Allergan's generics pharmaceuticals business. This strategic acquisition for Teva brings together two leading generics businesses with complementary strengths, R&D capabilities, product pipelines and portfolios, geographical footprints, operational networks and cultures. 

As a result of the transaction, Teva will be well positioned to thrive in an evolving global marketplace, to realize the opportunities the very attractive global and U.S. generics markets offer, and to deliver the highest-quality generic medicines at the most competitive prices, unlocking value to patients, healthcare systems and investors around the world.

The S&C team advising Teva was led by Mr. Frumkin, Mr. Krautheimer, Ms. Payne and Mr. Veeraraghavan. Mr. Emmerson and Mr. Perry advised on UK corporate matters, Mr. Estes and Mr. McKnight advised on financing matters, Mr. Holley and Mr. Rodriguez advised on antitrust matters, Mr. Wang advised on tax matters; Mr. Friestedt and Ms. Coleman advised on executive compensation and benefits matters, and Mr. Giuffra, Mr. Frawley and Mr. Savva advised on litigation matters.